Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Sep 15, 2025; 17(9): 106297
Published online Sep 15, 2025. doi: 10.4251/wjgo.v17.i9.106297
Published online Sep 15, 2025. doi: 10.4251/wjgo.v17.i9.106297
Comparative impact of antiviral therapies on postoperative recurrence risk in patients with hepatitis B virus-related hepatocellular carcinoma
Hua-Mei Liu, Xin Zhang, Hang-Ying Huang, Jia-Min Sun, Qing-Dong Tong, Department of Infectious Diseases, The Second Hospital of Longyan, Longyan 364000, Fujian Province, China
Author contributions: Liu HM, Zhang X, Huang HY, Sun JM, Tong QD contributed equally to this work; Liu HM, Zhang X, and Huang HY designed the research study; Sun JM and Tong QD performed the primary literature search and data extraction; Liu HM analyzed the data and drafted the manuscript; Sun JM and Tong QD revised the manuscript for important intellectual content; and all authors read and approved the final version submitted for publication.
Institutional review board statement: The study was reviewed and approved by the Second Hospital of Longyan Institutional Review Board, No. LYEY-KY-2025-004.
Informed consent statement: All study participants or their legal guardian provided informed written consent about personal and medical data collection prior to study enrolment.
Conflict-of-interest statement: The authors declare no conflicts of interest for this article.
Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author at
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Qing-Dong Tong, MD, Chief Physician, Department of Infectious Diseases, The Second Hospital of Longyan, No. 153 Dongxing Road, Xinluo District, Longyan 364000, Fujian Province, China. 13616906527@163.com
Received: March 21, 2025
Revised: April 15, 2025
Accepted: July 30, 2025
Published online: September 15, 2025
Processing time: 177 Days and 17.3 Hours
Revised: April 15, 2025
Accepted: July 30, 2025
Published online: September 15, 2025
Processing time: 177 Days and 17.3 Hours
Core Tip
Core Tip: This study compared the recurrence rate of hepatocellular carcinoma (HCC) after radical resection of HCC in patients treated with entecavir (ETV) or tenofovir fumarate (TDF) after propensity score matching. Results revealed that HCC recurrence was observed in 33 (66.0%) patients in the ETV group and 21 (42.0%) in the TDF group, and the risk for HCC recurrence was lower in the TDF group than in the ETV group (P = 0.016). The cumulative recurrence rates of HCC at 1, 3, and 5 years in the ETV and TDF groups were 26.0%, 58.0%, and 66.0%, and 18.0%, 38.0%, and 42.0%, respectively (P = 0.045).